Cillian King, PhD, is a managing director at EQT Life Sciences, one of Europe’s leading life sciences investors, where he manages the LSP Dementia Fund.

Prior to joining EQT Life Sciences, Cillian was an investment manager at Swanbridge Capital, a venture fund focused on early stage life sciences companies. He currently serves on the boards of Muna Therapeutics and Sairopa, and is a past board member of Pan Cancer T and Allero Therapeutics (exited).

Cillian was trained at VU University (Amsterdam, NL) and Massachusetts Institute of Technology (Cambridge, US) and holds degrees in molecular biology and a PhD in molecular neuroscience.